1
Return

When survival improves but quality of life does not: a model-based meta-analysis of immune checkpoint inhibitors

delete2026-07-11
delete0
PRE
AI
Y
Yimeng Sun
S
Shiwon Chang
K
Kayden Tang
M
Matthew R LeBlanc, PhD, RN
A
Adam C Palmer, PhD
M
Malidi Ahamadi, PhD
J
Jiawei Zhou, PhD *
DOI：10.1093/jnci/djag228delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
In immune checkpoint inhibitor (ICI) trials, overall survival (OS) benefits are well established, yet improvements in quality of life (QoL) are often inconsistent or absent in conventional analyses. This apparent discordance raises important questions: are QoL outcomes truly unrelated to survival, and how can QoL results be better utilized and interpreted?

Journal

J
JNCI: Journal of the National Cancer Institute
IF:
0
Papers:
194
Citations:
0

Organization

S
Sanofi
Scholars:
537
Papers: 136
Citations: 0
U
university of north carolina at chapel hill
Scholars:
1.4K
Papers: 573
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers